文献速递介入腹部DSACTMR

不可切除的系统化疗难治性肝转移瘤的经动脉化疗栓塞:一项回顾性单中心分析

Transarterial chemoembolization of unresectable systemic chemotherapy refractory liver metastases: a retrospective single-center analysis.
PubMed 文献 · Abdom Radiol (NY) · 2020-01-01

单中心回顾性分析2014年6月至2018年6月53例至少两线化疗失败的不可切除结直肠癌肝转移患者,TACE后客观影像学缓解率52.8%、疾病控制率79.2%,中位OS 15个月、中位PFS 6个月,2例(3.8%)发生严重并发症;作者结论认为TACE耐受良好且有效。

要点

  • 化疗难治性结直肠癌肝转移TACE后客观影像学缓解率52.8%、疾病控制率79.2%。
  • 中位OS 15个月(95%CI 13.1–16.9个月),中位PFS 6个月(95%CI 4.7–7.3个月)。
  • 同时性转移、肝外转移、Child-Pugh B级为OS和PFS的独立预后因素。

核心结论

  • TACE在不可切除的化疗难治性结直肠癌肝转移患者中耐受良好且有效,作者认为对该类患者TACE仍是较好的治疗选择。

研究设计与样本

  • 单中心回顾性研究,纳入2014年6月至2018年6月连续病历中至少两线化疗失败的结直肠癌肝转移患者53例,记录治疗反应、总生存、无进展生存及并发症。

关键影像表现/征象

  • 影像学客观肿瘤退缩率为52.8%,疾病控制率为79.2%。

诊断标准与关键数值

  • 原文未报告TACE的技术参数、栓塞终点或影像学缓解所依据的具体分级标准。

临床应用与阅片要点

  • 多因素分析显示同时性转移、肝外转移和Child-Pugh B级是OS和PFS的独立预后因素。
  • 亚组分析显示同时性肝转移和肝外转移影响患者预后,原发肿瘤部位(直肠、左半结肠、右半结肠)对预后无影响。
  • 2例(3.8%)发生严重并发症。

局限性

  • 原文标题和 Methods 明确为单中心回顾性研究。
  • 作者在结论中提出TACE对这些患者仍是较好的治疗,原文未报告需进一步研究等自我限定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The purpose of this study was to evaluate the therapeutic efficacy and safety of transarterial chemoembolization (TACE) in the treatment of patients with unresectable colorectal cancer liver metastases (CRCLM) who had failed systemic chemotherapy. In addition, the role of TACE in the treatment of CRCLM is also worth discussing.

METHODS: This single-center retrospective study evaluated the consecutive medical records of patients with CRCLM treated with TACE from June 2014 to June 2018, who had failed at least two lines of prior chemotherapy. Therapeutic response, overall survival (OS), progression-free survival (PFS), and complications were recorded.

RESULTS: Fifty-three eligible patients were included in our study. The objective tumor radiologic regression and disease control rates were 52.8% and 79.2%, respectively. Median OS and PFS were 15 months (95% confidence interval [CI] 13.1 months, 16.9 months) and 6 months (95% CI 4.7 months, 7.3 months), respectively. Multivariate analysis found that synchronous metastatic disease, presence of extrahepatic metastasis, and Child-Pugh score B were independent prognostic factor for OS and PFS. Two patients (3.8%) had severe complications. The results of subgroup analysis showed that synchronous liver metastasis and extrahepatic metastasis had an effect on the prognosis of patients, while the primary tumor sites (rectum, left, and right colon) had no effect on the prognosis.

CONCLUSIONS: TACE is well tolerated and effective in patients with unresectable chemotherapy refractory CRCLM. Meanwhile, the results of this study also indicated that TACE is still a better treatment for these patients.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Ren Y, Chen L, Huang S, et al. Transarterial chemoembolization of unresectable systemic chemotherapy refractory liver metastases: a retrospective single-center analysis. Abdom Radiol (NY). 2020. PMID: 32468211. doi:10.1007/s00261-020-02584-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。